logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10858314 B1

PDFFull Text
Date of Patent:
Dec. 08, 2020

Filed:

May. 26, 2016

Urea derivative or pharmacologically acceptable salt thereof

Applicant:

Kyorin Pharmaceutical Co., Ltd., Tokyo, JP;

Inventors:

Hiroyasu Takahashi, Miyagi, JP;

Hiroyuki Watanabe, Tochigi, JP;

Kiyoshi Fujii, Tochigi, JP;

Mitsuhito Shibasaki, Tochigi, JP;

Mikako Kawashima, Tochigi, JP;

Megumi Kamiya, Tochigi, JP;

Kohei Ohata, Tochigi, JP;

Assignee:

Kyorin Pharmaceutical Co., Ltd., Tokyo, JP;

Attorney:

BakerHostetler

Primary Examiner:

Kahsay Habte

Int. Cl.
CPC ...
C07C 275/30 (2006.01); C07C 275/42 (2006.01); C07C 275/50 (2006.01); C07D 231/12 (2006.01); C07D 239/36 (2006.01); C07D 271/07 (2006.01); C07D 271/113 (2006.01); C07D 285/08 (2006.01); C07D 285/135 (2006.01); C07D 413/04 (2006.01); C07D 333/16 (2006.01); C07D 333/28 (2006.01); C07D 263/34 (2006.01); C07D 271/06 (2006.01); C07D 213/61 (2006.01); C07D 261/08 (2006.01); C07D 307/79 (2006.01); C07D 285/12 (2006.01); C07C 317/32 (2006.01); C07C 317/40 (2006.01); C07D 263/32 (2006.01); C07C 311/51 (2006.01); C07D 257/04 (2006.01); C07D 273/04 (2006.01); C07D 277/28 (2006.01); C07D 271/10 (2006.01); C07D 249/08 (2006.01); C07D 311/58 (2006.01); C07D 249/04 (2006.01); C07D 417/12 (2006.01); C07D 413/12 (2006.01); C07D 249/12 (2006.01); A61P 31/18 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07C 275/30 (2013.01); A61P 29/00 (2018.01); A61P 31/18 (2018.01); A61P 35/00 (2018.01); C07C 275/42 (2013.01); C07C 275/50 (2013.01); C07C 311/51 (2013.01); C07C 317/32 (2013.01); C07C 317/40 (2013.01); C07D 213/61 (2013.01); C07D 231/12 (2013.01); C07D 239/36 (2013.01); C07D 249/04 (2013.01); C07D 249/08 (2013.01); C07D 249/12 (2013.01); C07D 257/04 (2013.01); C07D 261/08 (2013.01); C07D 263/32 (2013.01); C07D 263/34 (2013.01); C07D 271/06 (2013.01); C07D 271/07 (2013.01); C07D 271/10 (2013.01); C07D 271/113 (2013.01); C07D 273/04 (2013.01); C07D 277/28 (2013.01); C07D 285/08 (2013.01); C07D 285/12 (2013.01); C07D 285/135 (2013.01); C07D 307/79 (2013.01); C07D 311/58 (2013.01); C07D 333/16 (2013.01); C07D 333/28 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07B 2200/07 (2013.01); C07C 2601/02 (2017.05);
Abstract

The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.

Find Patent Forward Citations

Loading…